MAPK14 and amyotrophic lateral sclerosis: In summary, our pharmacological inhibitor screen revealed that WNT signaling and p38/MAPK are major drivers of FUS ALS MN loss, similar to observations in SOD1 E100G iPSC-derived MN (Bhinge et al., 2017).